echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Yangtze River acquires the right to develop and sell Daewoong Pharmaceutical's fexuprazan in China through a new 2.2 billion yuan agreement

    Yangtze River acquires the right to develop and sell Daewoong Pharmaceutical's fexuprazan in China through a new 2.2 billion yuan agreement

    • Last Update: 2021-04-14
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Recently, Daxiong Pharmaceutical announced that it has signed a license agreement with Haini Pharmaceuticals, a subsidiary of Yangtze River Pharmaceutical Group, authorizing the latter to develop and sell its gastroesophageal reflux treatment drug fexuprazan in China.


    According to the agreement, Haini Pharmaceuticals will be responsible for the clinical development of fexuprazan for the treatment of digestive system diseases, and will be responsible for the entire approval process of the drug in China.


    It is reported that as a new generation of proton pump inhibitor, fexuprazan can reversibly block the proton pump secreting gastric acid for the treatment of gastroesophageal reflux disease.


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.